A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Endo Pharmaceuticals

Status: Terminated

Conditions: Bladder Cancer; CIS

Study type: Observational

Funder types: Industry

Identifiers

NCT01314664

EN3329-402

Details and patient eligibility

About

The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females 18 years of age and older
• Diagnosed with NMIBC
• Prescribed intravesical valrubicin to treat NMIBC
• Understood and signed Informed Consent to participate

Exclusion criteria

• None